An ECJ decision to follow its Advocate General’s advice could doom the EU antitrust watchdog’s other cases targeting mergers that don’t meet revenue thresholds.
April 09, 2024 at 05:43 PM
3 minute read
The original version of this story was published on Law.com International
U.S. biotech company Illumina has received some encouraging news in its fight against the European Commission’s rejection of its approximately $8 billion acquisition of California blood-test startup Grail.
In a March 21 opinion, an influential adviser to the EU’s top appeals court said the commission’s antitrust watchdog, DG Competition, overstepped its authority by reviewing the transaction in 2021 and ordering Illumina to sell the company last year.
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Truly exceptional Bergen County New Jersey Law Firm is growing and seeks strong plaintiff's personal injury Attorney with 5-7 years plaintif...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
